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ABSTRACT 
Objective: In the search for new therapeutic products for the treatment of neurological disorders, medicinal plant research, worldwide, has 
constantly progressed, demonstrating the pharmacological effectiveness of different plant species in a variety of animal models. SOBEREX CAPSULE 
(SC) is a herbomineral formulation used by ayurvedic practitioners for treatment of depression. The present study was designed to generate 
scientific evidence for SC in animal models of depression in mice.  
Methods: The formulation was administered orally to the mice at a dose of 50 mg/kg for 14 d, and at the end of treatment animals were subjected 
to tail suspension test and the forced swimming test in mice.  
Results: The effect of SC at the dose of 50 mg/kg was comparable to that of reference antidepressant fluoxetine. The formulation and fluoxetine, at 
the doses tested, produced no significant effects on locomotor activity. These results demonstrated that SC had antidepressant effects without side 
effect.  
Conclusion: Thus, SC possesses antidepressant-like effects in mice, providing further support for the traditional use of the formulation against 
central nervous disorders. 
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INTRODUCTION 
According to the World Health report (WHO, 2001), approximately 
450 million people suffer from a mental or behavioral disorder, yet 
only a small minority of them receive basic treatment. This accounts 
to 12.3 % of the global burden of disease, and will rise to 15 % by 
2020 [1]. In the search for new therapeutic products for the 
treatment of neurological disorders, medicinal plant research has 
constantly progressed, demonstrating the pharmacological 
effectiveness of different plant species in a variety of animal models. 
In spite of the introduction of the tricyclic antidepressants (TCAs), 
selective reversible inhibitors of monoamine oxidize A (RIMAs), 
selective serotonin reuptake inhibitors (SSRIs) and specific 
serotonin-noradrenaline reuptake inhibitors (SNRIs), depression 
continues to be a major medical problem [2]. However, search for 
new antidepressant drug continues. The drugs of plant origin are 
gaining popularity and are being investigated for remedies of a 
number of disorders.  
Soberex capsule having a components such as extract of Brahmi 
(Bacopa monnieri), extract of Jatamansi (Nardostychas jatamsnsi), 
extract of Shankhpushpi (Convolvulus pluricaulis), extract of 
Sarpagandha (Rauwolfia serpentine), Vacha (Acorus calamus), 
Ashwagandha (Withania somnifera), Arjun (Terminalia arjuna), Akik 
Bhasma, Ustekhudus (Lavandula stoechas), Jyotismati Seed 
(Celestrus peniculatus), Khurasani Ajama (Hyoscyamus niger) have 
been used as an antianxiety agent and have shown positive effects. 
The remedies for stress-induced depression still need to be explored 
after being declared the second in regard to the disease burden 
worldwide. The present study was designed to evaluate the effect of 
oral treatment of formulation in various animal models of 
depression in mice. The study was undertaken to evaluate the 
efficacy of formulation in Forced swim test (FST), Tail suspension 
test (TST), and locomotor activity test for treatment of depression. 
MATERIALS AND METHODS 
All the plants used in the formulation were authenticated, and 
formulation was prepared by Virgo UAP Pharma Pvt. Ltd. Sanand, 
(Ahmedabad, Gujarat, India) named as a Soberex capsule (SC) on the 
basis of an official Ayurvedic formulary. 
Experimental animals 
Mice weighing 20-25 g were obtained from the animal facility of 
Zydus research center, Ahmedabad, were housed in a pathogen-free 
environment at the animal house of Institute of pharmacy, Nirma 
University. Animals were maintained under well controlled 
temperature 22±8 o
Experimental protocol 
C & humidity 55±5 % and 12h/12h light/dark 
cycle. They were kept in the well-ventilated animal house under 
natural photoperiodic conditions in polypropylene cages with free 
access to food and water ad libitum. All experiments and protocols 
described in the present study were approved by the Institutional 
Animal Ethics Committee (IAEC) of Institute of Pharmacy, Nirma 
University, Ahmedabad as per guidelines of the Committee for the 
Purpose of Control and Supervision of Experiments on Animals 
(CPCSEA), Ministry of Social Justice and Empowerment, Government 
of India. All the experiments described in the present study were 
conducted as per protocol number IPS/PCOL/CONS/12-13/1004 
dated 17-08-2012. 
All the animals were allowed to acclimatize in the test cage 7 d prior 
to experimentation. The mice were randomly divided into 9 groups 
of 3 set of experiment comprising 6 animals each. For each set mice 
grouped into three groups. Control, Control treated with SC (50 
mg/kg/day, p. o.), Control treated with fluoxetine (20 mg/kg/day, p. 
o.). The first 3 groups were randomized as set 1 animal. The test 
compound administered orally for 14 d before the experiments in a 
volume of 10 ml/kg. Animals were subjected to different tests like 
tail suspension test, forced swim test, and locomotor activity test. 
Open field test (OFT) for measurement of locomotor activity 
Open field test (OFT) was conducted in the mice as per the method 
described by Pawar et al. 2014 [3]. The open field apparatus is made 
of a wooden box (36 X 36 X 30 cm high). Its floor is divided into nine 
squares of equal dimensions (12 X 12 cm). For OFT, each mouse was 
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placed in the center of the arena. The locomotor activity of each 
mouse was assessed by counting the number of line crossings and 
rearing frequencies in the open field apparatus for 5 min. The 
apparatus was cleaned after each assessment to eliminate the 
possibility of any odor clues left by the previously tested mice. The 
experiments were conducted in dark and a sound proof room. 
Forced swimming test (FST) 
The studies were carried out on mice, according to the method of 
Porsolt, 1977 [4]. Briefly, the mouse was individually forced to swim 
for 6 min, in glass cylinders (20 cm in height; 14 cm in diameter), 
containing fresh water up to a height of 10 cm at 24-26 °C. After 6 
min, they were removed and dried with a towel. They were again 
forced to swim in a similar environment for a period of 6 min 24 h 
later. The duration of immobility was measured during the final 4 
min interval of the test. 
Tail suspension test (TST) 
The tail suspension test was based on the method of Steru et al., 
1985 [5]. The mouse was individually suspended by the tail with 
clamp (1 cm distance from the end) for 6 min in a box (25/25/30 
cm) with the head 5 cm to the bottom. Testing was carried out in 
a darkened room with minimal background noise. The duration 
of immobility was observed during the final 4 min interval of the 
test. 
RESULTS 
Effects of SC on the duration of immobility time in the mouse 
tail suspension test 
Effects of oral administration of SC and fluoxetine on the duration of 
immobility in the mouse tail suspension test were shown in fig. 1. 
The effects of SC on immobility time at the doses of 50 mg/kg 
appeared to be comparable to effect produced by fluoxetine after 14-



























Fig. 1: Effects of SC on the duration of immobility in the mouse 
tail suspension test. Values expressed as mean±SEM of 6 
animals each, # significantly different from disease control 
group (p<0.05). DC-Disease control, DTSC-Diseased animals 
treated with SC (50 mg/kg), DFT-Diseased animal treated with 
fluoxetine (20 mg/kg) 
 
Effects of SC and fluoxetine on the duration of immobility in the 
mouse forced swimming test 
Effect of SC and fluoxetine on the duration of immobility in the 
mouse forced swimming test was shown in fig. 2. The SC at the dose 
of 50 mg/kg exhibited significant immobility reduction (46.20 %) 
after 14-day treatment. Fluoxetine at the dose of 20 mg/kg 
significantly produced a reduction in immobility (40.00 %).  
However, the effect of SC at the dose of 50 mg/kg appeared to be 
less potent than that of fluoxetine (40.00 %) after 14-day 
treatment (fig. 2). 
Effects of SC on mouse locomotor activity 
In this study, the SC and fluoxetine at the dose of 50 mg/kg and 20 
mg/kg respectively, which significantly reduced immobility time in 
mouse tail suspension and in the mouse forced swimming tests, 
produced no significant difference in locomotor activity compared 




























Fig. 2: Effects of SC on the duration of immobility in the forced 
swimming test. Values expressed as mean±SEM of 6 animals 
each, # significantly different from disease control group 
(p<0.05). DC-Disease control, DTSC-Diseased animals treated 
with SC (50 mg/kg), DFT-Diseased animal treated with 
fluoxetine (20 mg/kg) 
 
Table 1: Effects of SC and fluoxetine on numbers of grooming 
and rearing in the in the open-field behavior test 
Groups Numbers of grooming  Numbers of rearing  
 CON 52.07±10.02  50.33±10.12 
 DTSC 49.67±6.54# 54.10±7.27 # 
 DFT 47.17±9.13 # 49.15±9.43# 
Values expressed as mean±SEM of 6 animals each, # significantly 
different from disease control group (p<0.05). CON-Disease control, 
DTSC-Diseased animals treated with SC (50 mg/kg), DFT-Diseased 
animal treated with fluoxetine (20 mg/kg). 
 
DISCUSSION 
Mood disorders are among the most prevalent forms of mental 
illness. Depression is one of the major mood disorder, characterized 
by a combination of symptoms that interfere with a person’s ability 
to work, sleep, study, eat and enjoy once-pleasurable activities and 
prevents a person from functioning normally. Depression is an 
important global public health problem due to both its relatively 
high lifetime prevalence and the significant disability that it causes. 
The demand for curbing depression and other mental health 
conditions is on the rise globally [6]. Current antidepressants, which 
target monoamines, only produce remission in 30 % of patients [7]. 
Patients with major depression have changes in brain monoamine 
neurotransmitters, specifically norepinephrine, serotonin, and 
dopamine [8]. In spite of its prevalence and severe impact, the 
efficacy of currently available antidepressant, is often inconsistent 
and many of them exert undesirable side effects such as 
hypotension, arrhythmia, insomnia and sexual dysfunction [9]. 
The tail suspension and forced swimming tests were two behavioral 
tests in a rodent that predicted the clinical efficacy of many types of 
antidepressant treatments [10, 11]. Forced swimming test is a 
commonly used behavioral despair model of depression. This model is 
widely employed in rodents to predict antidepressant potential by 
several different classes of antidepressant drugs. SC is a herbomimeral 
formulation, and its major constituents are Bacopa monnieri, 
Nardostychas jatamsnsi, Convolvulus pluricaulis, Rauwolfia serpentine, 
Acorus calamus, Withania somnifera, Terminalia arjuna, Lavandula 
stoechas, Celestrus peniculatus, Hyoscyamus niger and Akik Bhasma. 
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No information is available about the antidepressant activity of the 
combination of all these constituents. We studied the SC on the 
immobility behaviours in mice in two animal models tail suspension 
and forced swimming tests. The oral doses for 14 d significantly 
decreased the duration of immobility in the tail suspension test and 
the forced swimming test in mice. These behavioral effects of SC at 
the dose of 50 mg/kg were comparable that of fluoxetine after 14-
day treatment. As changes in immobility may be due to changes in 
locomotor activity caused by central nervous system stimulating 
agents, mice were tested in the open field test. Neither the SC 
norfluoxetine, at the doses tested, produced significant effects on 
locomotor activity. The results showed that antidepressant activity 
is not due to CNS stimulant effect of the formulation. 
The components present have been well established to show 
antianxiety activity, and also, some constituent showed 
antidepressant activity. Extract of Jatamansi showed antidepressant 
activity due to decrease in GABA level as its extract interacts with 
the GABA receptors [12]. Also, it reduces MAO-A and MAO-B activity, 
hence producing antidepressant activity by inhibiting the 
metabolism of monoamines [13]. The chloroform fraction of the 
total ethanolic extract of Convolvulus pluricaulis elicited a significant 
antidepressant-like effect in mice by interaction with the adrenergic, 
dopaminergic, and serotonergic systems [5]. Acorus calamus has 
been used as a prophylactic for the prevention of depression [14]. 
Withania somnifera used as a mood stabilizer and hence can be used 
in depression [15]. Terminalia arjuna used as an adjuvant therapy in 
the treatment of depression mediated mainly through the 
monoamine pathway [16]. Celastrus paniculate seed oil showed 
significant antidepressant-like by inhibition of MAO-A activity, a 
decrease in plasma nitrite levels; and through scavenging of free 
radicals, reduction in plasma cortisol levels [17,18]. Hyoscyamus 
niger show antidepressant-like activity in forced swim test and tail 
suspension test in mice [19]. The standardized methanolic extract of 
Bacopa monniera showed potential antidepressant activity in rodent 
models of depression and was comparable to that of imipramine 
[20]. Reserpine, active chemical constituent present in Rauwolfia 
serpentina reported having a beneficial role in mental depression in 
patients [21]. Similarly, Lavandula stoechas has been reported to be 
used for the treatment of various psychological disorders [22]. 
Various preparations containing Akik Bhasma have been reported to 
exhibit anxiolytic, antidepressant activities with a wide margin of 
safety. Literature study shows that all constituents of SC possess 
antidepressant properties individually. The data from our present 
study shows that all these constituents in combination (SC) possess 
antidepressant effect.  
CONCLUSION 
In conclusion, the results of this study showed that the SC appear to 
have an antidepressant-like effect in mice in the forced swimming 
and tail suspension test. These data provide further support to the 
traditional use of formulation in the folk medicine against central 
nervous disorders. Although the precise mechanism involved in the 
observed antidepressant activity is not yet clear, the experimental 
observations suggest a possible direct or indirect facilitation of the 
central serotonergic transmission for the species studied. Further 
research is required to elucidate their mechanism of action of 
constituents present in the formulation. 
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